GSK, other drugmakers bet on post-Brexit UK science

LONDON: Britain won a vote of confidence from its economically important life sciences sector on Wednesday as five drug companies committed to invest in the country under the government’s industrial strategy plans after Brexit.

The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of the industry as Britain prepares to leave the European Union.

Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

In a bid to soften the blow, the government has backed a report by immunologist and geneticist John Bell designed to boost the pharmaceutical sector via fresh public-private collaborations.

That has paved the way for the Life Sciences Sector Deal, which will see GSK invest 40 million pounds ($54 million) of new money in genomic research, including a plan to sequence DNA from all 500,000 volunteer participants enrolled in UK Biobank, the world’s most detailed biomedical database.

GSK’s head of research Patrick Vallance said the deal showed Britain remained an attractive place for drug discovery, but he cautioned: “The UK needs to recognize going forward that science is an international endeavor, not a parochial endeavor.”

Other investments include plans by Johnson & Johnson and the Medicines Co to work on new clinical trials, and genetic research by AstraZeneca.

U.S. drugmaker Merck & Co had already announced plans to expand UK research operations under the deal last week.